PTEN and melanoma: Likewise, Held and colleagues [21] reported that ~25% of BRAF-V600E melanomas are intrinsically resistant to vemurafenib in the context of normal PTEN and Rb expression, supporting the notion that loss of these tumor suppressors is not indispensable for intrinsic drug resistance.